As shown in Table 1, Figure 2B and Figure 4A,C, the sensitivities of AFP and autoantibody to GNAS in HCC patients were 58.3% and 40.6% in the discovery phase, and 49.6% and 47.8% in the validation phase, respectively. This evidence concerns the gene GNAS and hepatocellular carcinoma.